{"gao_id": "GAO-17-749T", "published": "2017-07-18T12:00:00Z", "released": "2017-07-18T08:00:00Z", "summary": "Under the 340B Drug Pricing Program, if drug manufacturers want Medicaid to cover their drugs, they are required to sell outpatient drugs at discounted prices to covered entities\u2014such as eligible clinics and hospitals. Our 2011 report found weaknesses in the Health Resources & Services Administration's (HRSA) oversight of the 340B program. This testimony describes HRSA\u2019s progress in addressing our recommendations : it now audits entities...", "title": "Drug Discount Program: Update on Agency Efforts to Improve 340B Program Oversight", "topics": ["Drug prices", "Pharmaceutical industry", "Pharmacy", "Medicaid", "Program integrity", "Health Care", "Eligibility criteria", "Audits", "Drugs", "Drug pricing", "Internal controls", "Prices and pricing", "Compliance oversight"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-17-749t", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-17-749t-highlights.pdf"}, {"title": "Full Report (18 pages)", "url": "https://www.gao.gov/assets/gao-17-749t.pdf"}, {"title": "Accessible PDF (19 pages)", "url": "https://www.gao.gov/assets/690/686155.pdf"}]}